Oncology Institute announces Q3 2022 results and FY2022 guidance via slide deck

Oncology Institute, Inc.

2022-Q3 EPS reported -$0.03 revenue$181,059,000

Slide presentation includes financial results for three and nine months ended Sept 30, 2022.
Company provided updated business guidance for the year ending Dec 31, 2022.
Presentation issued on Nov 15, 2022; common stock (TOI) and warrants (TOIIW) traded on Nasdaq.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oncology Institute, Inc. reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

Item 2.02. Results of Operations and Financial Condition On November 15, 2022, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three and nine months ended September 30, 2022 and certain other financial information. A copy of the presentation is furnished hereto as Exhibit 99.1, which are incorporated by reference herein.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-029935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.